Fatty Acid Oxidation Mediated by Malonyl-CoA Decarboxylase Represses Renal Cell Carcinoma Progression
Open Access
- 20 September 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (23) , 3920-3939
Abstract
Fatty acid metabolism reprogramming is a prominent feature of clear cell renal cell carcinoma (ccRCC). Increased lipid storage supports ccRCC progression, highlighting the importance of understanding the molecular mechanisms driving altered fatty acid synthesis in tumors. Here, we identified that malonyl-CoA decarboxylase (MLYCD), a key regulator of fatty acid anabolism, was downregulated in ccRCC, and low expression correlated with poor prognosis in patients. Restoring MLYCD expression in ccRCC cells decreased the content of malonyl CoA, which blocked de novo fatty acid synthesis and promoted fatty acid translocation into mitochondria for oxidation. Inhibition of lipid droplet accumulation induced by MLYCD-mediated fatty acid oxidation disrupted endoplasmic reticulum and mitochondrial homeostasis, increased reactive oxygen species levels, and induced ferroptosis. Moreover, overexpressing MLYCD reduced tumor growth and reversed resistance to sunitinib in vitro and in vivo. Mechanistically, HIF2α inhibited MLYCD translation by upregulating expression of eIF4G3 microexons. Together, this study demonstrates that fatty acid catabolism mediated by MLYCD disrupts lipid homeostasis to repress ccRCC progression. Activating MLYCD-mediated fatty acid metabolism could be a promising therapeutic strategy for treating ccRCC. Significance: MLYCD deficiency facilitates fatty acid synthesis and lipid droplet accumulation to drive progression of renal cell carcinoma, indicating inducing MYLCD as a potential approach to reprogram fatty acid metabolism in kidney cancer.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (NO. 82203099)
- National Natural Science Foundation of China (NO. 82173294)
- National Natural Science Foundation of China (NO. 82103000)
- the Joint Construction Project between Medical Science and Technology Research Project of Henan Province (NO. LHGJ20220335)
- Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University (NO.QNCXTD2023023)
- Training Program for Middle-aged and Young Discipline Leaders of Health of Henan Province (NO. HNSWJW-2021004)
This publication has 50 references indexed in Scilit:
- Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell CarcinomaClinical Cancer Research, 2013
- Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosisNature Medicine, 2012
- De novo Lipogenesis Protects Cancer Cells from Free Radicals and Chemotherapeutics by Promoting Membrane Lipid SaturationCancer Research, 2010
- Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cellsOncogene, 2009
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal TumorsClinical Cancer Research, 2008
- Malonyl-CoA, a Key Signaling Molecule in Mammalian CellsAnnual Review of Nutrition, 2008
- Loss of the Tuberous Sclerosis Complex Tumor Suppressors Triggers the Unfolded Protein Response to Regulate Insulin Signaling and ApoptosisMolecular Cell, 2008
- Expression of genes regulating Malonyl‐CoA in human skeletal muscleJournal of Cellular Biochemistry, 2006
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell, 2005
- Alteration of the Malonyl-CoA/Carnitine Palmitoyltransferase I Interaction in the β-Cell Impairs Glucose-Induced Insulin SecretionDiabetes, 2005